



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

10/531385

Bescheinigung

Certificate

Attestation

REC'D 10 NOV 2003

WIPO

PCT

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02023332.6

1B/03/4597

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
im Auftrag  
For the President of the European Patent Office  
Le Président de l'Office européen des brevets  
p.o.

R C van Dijk



Anmeldung Nr:  
Application no.: 02023332.6  
Demande no:

Anmelddetag:  
Date of filing: 18.10.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Rescom GmbH  
Oberneuhofstrasse 5  
6341 Baar  
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se referer à la description.)

Diagnosis of glaucoma by complex autoantibody repertoires in body fluids

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

G01N33/48

An Anmelddetag benannte Vertragstaaten/Contracting states designated at date of  
filling/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

## Diagnosis of glaucoma by complex autoantibody repertoires in body fluids

### Background of the invention

5      Glaucoma, one of the leading causes of blindness worldwide<sup>1</sup>, represents a group of ocular disorders that are responsible for loss of retinal ganglion cells and their axons, damage to the optic nerve, and gradual loss of visual field. People of all age-groups can be affected by this disease. At the age of 70 about seven percent of the population are suffering from glaucoma. Unlike other eye disorders, the causes of glaucoma and the best way to treat

10     them are still not completely investigated. The optic nerve head is considered the earliest site of nerve damage in glaucoma. The damage of these nerve fibers causes retinal ganglion cell death through retrograde degeneration. This can lead to total and irreversible blindness.

15     Although elevated intraocular pressure can be an important risk factor of glaucoma, it is no longer considered as an essential part of the definition of the disease, since some glaucomatous patients have normal intraocular pressures<sup>2</sup>. Only 76% of the patients with glaucoma have an intraocular pressure higher than 21 mm Hg<sup>3</sup>. Intraocular pressure of about 16% of glaucomatous eyes was never recorded above 21 mm Hg. Thus, a more

20     effective diagnostic criterion is necessary.

Currently, the most important screening methods for glaucomatous patients include tonometry, ophthalmoscopy and perimetry. Despite its well-known limitations, measuring the intraocular pressure (tonometry) is the most common method for glaucoma screening.

25     Tonometry has a sensitivity and specificity of about 65 percent. Ophthalmoscopy is a method for examining optic nerve head morphology. But the usefulness of this method is highly dependent on the skills of the examiner. Perimetry permits diagnosis of visual field loss, which is an indicator for ganglion cell death. But this method allows only detecting severe damage at an advanced stage of the disease. Therefore, a diagnostic method is

30     needed which is more objective and more sensitive and can be applied at an earlier stage in the evolution of the disease (i.e. before irreversible damage is manifest).

There are different kinds of glaucoma. Because the pathophysiology, clinical presence and treatment of the different types of glaucoma are so varied, there is no single definition that adequately encompasses all forms. The most common form is primary open-angle glaucoma (POAG), characterized by optic nerve damage and high intraocular pressure. But

5 there is also a high number of patients who never had elevated intraocular pressure; this form of glaucoma is usually called normal tension glaucoma (NTG). There are several other forms of primary and secondary glaucoma. There is not only adult onset glaucoma but there are also juvenile forms of glaucoma.

10 10 In some patients there is evidence for an autoimmune mechanism being responsible for glaucomatous injury to the optic nerve. Their glaucoma constitutes an organ-specific autoimmune disease, characterized by immune-mediated tissue destruction occurring in a limited range of tissue types or cells<sup>4</sup>.

15 15 Several specific antibodies have been detected in serum samples of glaucomatous patients.

The different families of heat shock proteins (HSPs) were detected in sera of patients with glaucoma like POAG or NTG. Heat shock proteins can be divided into different groups on the basis of their molecular weight, such as HSP-90 (90 kilo Dalton), HSP-70 (70 kDa),

20 20 HSP-60 (60 kDa), and small heat shock proteins (25 to 30 kDa). Heat shock proteins, also called stress proteins, serve as cellular chaperones<sup>5</sup> and as protectors for the whole organism. Heat shock proteins appear everywhere in normal tissue. By carrying immunogenic peptides, they are capable of triggering an immune response. They are considered neuroprotective and are expressed as a response to stress conditions such as

25 25 ischemia or excitotoxicity. But people with reduced or elevated levels of heat shock proteins could be lacking this neuroprotective factor. This deficiency might be a possible cause for the development of glaucoma. High titers of auto-antibodies to heat shock proteins could lead to optic neuropathy in these patients<sup>6</sup>. In patients with glaucoma, elevated serum auto-antibodies against small heat shock proteins have been found<sup>7</sup>. These

30 30 small heat shock proteins include  $\alpha$ -crystallins ( $\alpha$ A-crystallin and  $\alpha$ B-crystallin subunits) and HSP-27.  $\alpha$ -Crystallin is the predominant structural protein of the ocular lens and is also found in retinal cells. Hsp-27 antibody can enter retinal cells and this can lead to apoptosis of these cells<sup>8</sup>.

No association between the serum HSP antibody titers and optic disc parameters or peripapillary atrophy parameters has been found<sup>9</sup>.

5 Wax et al. developed an animal model to back up the thesis that auto-antibodies can be a cause of glaucoma<sup>10</sup>. Rats were immunized with Hsp27 and showed a degeneration of neurons in the retinal ganglion cell layer.

10 Antibodies against human vimentin and human glial fibrillary acid protein (GFAP) were detected in human optic nerve astrocytes exposed to elevated hydrostatic pressure<sup>11</sup>. The astrocytes developed an increased synthesis and redistribution of vimentin and GFAP.

15 Anti-Ro/SS-A (Sjögren syndrome A; also commonly called Ro antigens) antibodies were detected in patients with normal tension glaucoma<sup>12</sup>.

20 Romano et al. tested sera from glaucoma patients for anti-rhodopsin antibodies against retinal antigens<sup>13</sup>. Those patients had a priori clinically diagnosed POAG or NTG. Western blots of these sera showed antibodies against a 40-kDa antigen which was later identified as rhodopsin.

25 Serum antibodies that bind to human optic nerve head proteoglycans, including chondroitin sulfate and heparin, are found in patients with glaucoma<sup>14</sup>. Glycosaminoglycans (GAGs) play an important role as membrane proteins; they are components of extracellular matrix in the optic nerve head.

30 Serum auto-antibodies against gamma-enolase ( $\gamma$ -enolase) in retinal ganglion cells of glaucomatous patients have been detected by Maruyama et al<sup>15</sup>. These antibody levels were elevated in patients with glaucoma and were found in approximately 20% of glaucomatous patients.  $\gamma$ -Enolase is a neuron-specific enolase.

35 Lymphocytes in the blood of glaucoma patients were examined for antigens by Yang et al. These analyses showed that sera from patients with glaucoma have elevated small

interleukin-2 (sIL-2) levels<sup>16</sup>. sIL-2 is produced by T-cells and increases the level of other cytokines and antibodies.

Glutathione S-transferase (GST) antibodies were detected in glaucomatous patient sera<sup>17</sup>.

5 These antibodies bound against bovine retina. GST is expressed in tissue cytosols and membranes. It is present in the central nervous system, the retina, and throughout the whole body.

Tumor necrosis factor (TNF)- $\alpha$  and TNF- $\alpha$  receptor-1 are elevated in the retina of

10 glaucoma eyes compared to healthy donors<sup>18</sup>. Tezel et al. found TNF- $\alpha$  in glaucomatous eye was more intense in retinal areas close to the optic nerve head than in the periphery. TNF- $\alpha$  production is increased in retinal glial cells after exposure to elevated hydrostatic pressure or insulted ischemia<sup>19</sup>. High TNF- $\alpha$  levels lead to apoptosis by driving axonal degeneration<sup>20</sup>. Methods for treating glaucoma by inhibiting TNF- $\alpha$  are subject of patent

15 application WO 01/58469.

Antiphosphatidylserine (APS) antibodies have been detected in patients with normal tension glaucoma<sup>21</sup>. The NTG patients showed higher levels than healthy control subjects and patients with primary open angle glaucoma. Antiphosphatidylserine antibodies are a

20 subspecies of antiphospholipid antibodies (APL) and bind to phosphatidylserine molecules. Other subspecies are cardiolipin (ACL) and  $\beta$ 2-glycoprotein ( $\beta$ 2GP). Through this cascade the antibodies may be responsible for causing thrombosis. Cardiolipin binds to apoptotic cells which leads to an increased level of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ). Therefore, they play an important role in thrombosis development.

25

Myocilin/TIGR is expressed in optic nerves and trabecular meshwork of glaucomatous eyes<sup>22</sup>. TIGR is the former name of myocilin. The researchers observed a loss of myocilin in glaucomatous eyes. Its expression in the trabecular meshwork is thought to be responsible for the elevated intraocular pressure associated with some forms of

30 glaucoma<sup>23</sup>. Mutations of the TIGR gene increase the risk of early-onset glaucoma. The presence of the apolipoprotein E (ApoE) allele is an indicative of an increased risk of developing early-onset glaucoma, see patent application WO 00/68429.

A human transcription factor named FKHL7 is expressed most abundantly in the eye. Patent application WO 99/53060 describes this factor and its use in treating a diagnosing glaucoma.

5 Optineurin antibody has been detected in whole-cell extracts from patients with adult-onset primary open-angle glaucoma<sup>24</sup>. Optineurin may be part of the tumor necrosis factor- $\alpha$  signaling pathway. It is expressed in trabecular meshwork, ciliary epithelium, and retina.

10  $\gamma$ -Synuclein proteins occur in the optic nerve of glaucomatous eyes in a significantly higher level than in control eyes without glaucoma<sup>25</sup>. Synucleins contribute to the pathology of neuronal degeneration. All three members of synucleins ( $\alpha$ -,  $\beta$ -, and  $\gamma$ -synuclein) are expressed in retina and optic nerve. The bovine orthologue of  $\gamma$ -synuclein, synoretin, is mainly localized to the nuclear and synaptic regions of retinal cells<sup>26</sup>.

15 Testing for serum auto-antibodies in the clinical evaluation of neuropathy syndromes is widely practiced. Auto-antibodies can serve as markers in diagnosis and can lead to prognosis and treatment. Although some auto-antibodies in the sera of glaucoma patients have been identified and correlated with the glaucoma disease, as described hereinbefore, many still remain unknown.

20 Western blotting has surfaced as a powerful tool for detecting specific auto-antibodies in immune diseases. Complicating the straightforward identification of pathogenically relevant antigens, however, is that normal sera contain large amounts of natural antibodies which manifest themselves in complex staining patterns<sup>27,28</sup>. Thus, it can complicate the 25 differentiation of disease-associated auto-antibodies from the complex background of "auto-immune noise", i.e. naturally occurring auto-antibodies. Most of previous studies evaluated one or a few specific disease-related antibodies and have screened only a limited number of purified homologous or heterologous proteins as antigens by means of ELISA or RIA. A diagnosis based on these antibodies was impossible to establish. On the other 30 hand Western blotting has evolved as the most important tool to demonstrate auto-antibodies in auto-immune diseases because it permits simultaneous screening for a wide spectrum of different auto-antigens. A recent new technique, capable of analyzing these complex staining patterns of Western blots simultaneously, is based on digital image

analysis. This technique has been successfully used in studies of myasthenia gravis, Graves' disease and experimental uveitis<sup>29,30,31</sup>.

### **Summary of the invention**

5

The invention relates to a method for the diagnosis of glaucoma based on the composition of auto-antibodies against ocular antigens in body fluids of an individual. The method is characterized in that in a first step, auto-antibodies against ocular antigens are detected and measured in body fluids of an individual, and, in a second step, the auto-antibody pattern is  
10 correlated with corresponding patterns of healthy individuals and glaucoma patients.

10

The invention further relates to a method for assessing an individual's risk for developing glaucoma with or without an increased intraocular pressure by analyzing the auto-antibody repertoire in the individual's body fluids against ocular antigens as biomarkers for the  
15 diagnosis of glaucoma.

The invention further relates to kits for use in the method of the invention.

### **Detailed description of the invention**

20

The invention relates to a method for the diagnosis of glaucoma based on the composition of auto-antibodies in body fluids of patients. The term "glaucoma", as used herein, refers to all kind of primary open-angle glaucoma, including both juvenile-onset and adult-or  
25 late-onset glaucoma, pseudoexfoliation (PEX) syndrome and PEX glaucoma, with or without an elevated intraocular pressure, and to normal pressure glaucoma (normal tension glaucoma, NTG, or low-tension glaucoma, LTG).

30

In the method of the invention, the complex auto-antibody repertoires in body fluids of patients are used to set up a diagnosis and prognosis for the development and course of glaucoma. In the first step, the method detects the auto-antibodies against ocular antigens, e.g. against retinal antigens, optic nerve antigens, optic nerve head antigens, trabecular meshwork antigens, uveal antigens, or a mixture of them, in body fluids of an individual.  
"Body fluids" includes all fluids containing antibodies such as sera, tears, saliva, urine,

aqueous humour, vitreous body of the eye, etc. In the second step, the auto-antibody pattern is correlated with corresponding patterns of healthy individuals and glaucoma patients, in particular patients with different types of glaucoma. The invention also relates to the method of comparison of complex auto-antibodies patterns by calculation.

5

Detection of auto-antibody pattern may be by conventional Western blot techniques. However, the method of the invention also includes the use of other commercially available or experimental detection techniques such as chemiluminescence assays, ELISA, RIA, and techniques based on microarray chips, such as SELDI-TOF-type (surface-enhanced laser desorption/ionization in time-of-flight mass spectrometry; available e.g. under the trade name ProteinChip™ Array, from Ciphergen, Fremont, CA, USA), matrix assisted laser desorption/ionization (MALDI) mass spectroscopy, or other antibody-based chip array techniques (e.g. from BD Biosciences Clontech, Heidelberg, Germany).

15

The SELDI-TOF technique allows mass screening for auto-antibodies in a very reliable, fast, and extremely sensitive manner. For example, the ProteinChip™ system (Ciphergen) uses protein chip arrays and SELDI-TOF technology for capturing, detection, and analysis of proteins without labelling and without the need for chemical modification. The micro-scale design of the arrays allows the analysis of very small quantities of proteins. Arrays with biological activated surfaces are used that permit antibody capture studies. Preferably, protein-A-chips are incubated with sera of patients, then treated with a complex solution of auto-antigens. If the protein-A bound auto-antibodies recognize their antigens, these proteins can be separated by their molecular masses and detected by mass spectrometry. At higher molecular weights (>30kDa) the detection sensitivity of this on-chip method is comparable to conventional Western blotting. At lower molecular weights, the sensitivity of the Western blot technique is easily surpassed by the on-chip method. The on-chip procedure is quite easy to use, much less time consuming than Western blotting, and much more sensitive at least in the low molecular weight range.

20

25

30

Antibody-based chip arrays (e.g. Clontech) facilitate the diagnosis process by just spotting onto a micro-chip appropriate antigens that subsequently are recognized by their antibodies in the sera of patients.

After detection, the complex auto-antibody repertoires of body fluids are read in a digital image analysis system or other device for digitization, and subsequently analyzed by multivariate statistical techniques, e.g. analysis of discriminant, and/or artificial neural networks. Artificial neural networks learn from experience, not from programming. They  
5 are fast, tolerant of imperfect data, and do not need formulas or rules. Artificial neural networks are able to generalize and extract consistent features of patterns used to train them. In the present invention, the artificial neural network is "trained" to recognize the antibody patterns of glaucoma patients. The preferred artificial neural network used in the invention is the multiple layer feedforward network (MLFN) with the backpropagation  
10 training algorithm. This kind of network is typically formed by three layers: The input layer receives information from the "external world". The output layer presents the results to the connected devices. A layer of hidden neurons is sandwiched between them. Networks are trained by presenting known samples to them. The network attempts to change the function (weight) of each neuron until all training samples are classified  
15 correctly.

Other types of artificial neural networks may be used, e.g. self-propagation procedures, probabilistic neural networks, other kind of training algorithms, pruning techniques, and genetic algorithms.

20 These data analysis techniques differentiate between healthy individuals and glaucoma patients by considering the whole complex antibody pattern of each patient. By comparing the antibody pattern of a patient with suspected glaucoma with the antibody pattern in samples of other glaucoma patients and healthy individuals, the method can calculate to  
25 which clinical group the auto-antibody pattern of a patient with unknown pathology reveals the highest similarity.

30 The method of the invention not only includes the computational techniques as demonstrated herein, but also similar technologies, e.g. the use of other pattern matching techniques, other classifying statistical techniques or other methods to acquire the antibody-antigen reaction data of individuals.

In this complex antibody repertoire used, some of the antigen-antibody reactions are already known and described by others, as described in the background section. Further antibody-antigen interactions analyzed with the method of the invention are still unknown.

5 Several antigen-antibody-reactions are significantly higher in healthy individuals than in glaucoma patients. Reactivities which are absent in glaucoma patients are also used in the analysis of the antibody repertoires according to this invention. They contribute to higher sensitivity and specificity of the diagnostic method. The use of auto-antibodies that are not present or have or lower reactivity in auto-immune patients compared to controls for 10 diagnosing auto-immune diseases is also part of this invention.

The method of this invention uses the increase or decrease of auto-antibodies in diseased patients, compared to controls, as "biomarkers" for the diagnosis of the disease. This implies that knowledge about the identity of those antibodies is not needed for a reliable 15 diagnosis of the disease. No single auto-antibody reliably distinguishes glaucoma patients from healthy individuals.

Although the method is described for the diagnosis of glaucoma patients, it can also be used for the assessment of a (healthy) individual's risk for developing glaucoma with or 20 without an elevated intraocular pressure. Furthermore, the described method is useful for assessment of progression and/or severeness of glaucoma. For that purpose the change in the antibody pattern over time and corresponding computational and pattern matching techniques are used.

25 Kits for diagnosis of glaucoma according to the invention are based on conventional Western-blotting technique, on protein chip approaches or other techniques useful in the method of this invention. A kit may comprise a ready-to-use antigen mixture, chemicals and materials needed to perform the biochemical analysis, e.g. Western blots or biochips, and, optionally, a bundled computer software including the specialized algorithm to detect 30 glaucoma in the antibody pattern of patients. Kits according to the invention may be for use by a doctor or even a patient on its own, or for a professional diagnostic service laboratory center.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

5

### **Description of the Figures**

**Figure 1:** Antigen-antibody reactions against retinal antigens from Western blots plotted (Scanner units U) vs. their molecular weight (kDaltons, x-axis).

10 1: healthy control subjects (CO); 2: patients with primary open-angle glaucoma (POAG);  
3: patients suffering from ocular hypertension (OHT); 4: patients with normal tension glaucoma (NTG).

**Figure 2:** Antigen-antibody reactions against optic nerve head antigens (Scanner units U) plotted vs. their molecular weight (kDaltons, x-axis).

15 1: healthy control subjects (CO); 2: patients with primary open-angle glaucoma (POAG);  
3: patients suffering from ocular hypertension (OHT); 4: patients with normal tension glaucoma (NTG).

20 **Figure 3:** ROC (responder operating characteristic) scatter plot (true-positive vs. false positive) for the diagnosis of glaucoma by means of complex auto-antibody repertoires. The calculation of the area under curve (AUC) results in a r-value of 0.85 (good diagnostic test).

### **25 Example**

A total of 82 patients are divided into four groups: healthy volunteers without any ocular disorders (n=29), patients with primary open angle glaucoma (POAG, n=18), ocular hypertension (OHT, n=17), and normal tension glaucoma (NTG, n=18). All groups are

30 matched for age and gender. The sera of patients are tested against Western blots of retinal and optic nerve head antigens. After giving their informed consent blood is taken from all patients. Those samples are centrifuged and the serum stored for later examination.

Retinas from bovine eyes are dissected. They are homogenized in sample buffer (1 M Tris, pH 7.5; 10% SDS; DTT; bromophenol blue, pH 6.8), and separated by centrifugation (15000 rpm for one hour). The samples are cooked and homogenized several times. The pellet is discarded and the supernatant is stored for later analysis.

- 5 The retina extracts are used for 13.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using MultiGel-Long (Biometra, Goettingen, Germany). After electrophoresis the gels are transferred to nitrocellulose membrane Protran BA 83 (Schleicher and Schuell, Dassel, Germany) by using a Semi-Dry Blotter (Biometra, Goettingen, Germany). After blotting the membranes for one hour, the quality of the transfer is checked by staining the nitrocellulose with Ponceau S solution (Sigma, Munich, Germany).
- 10 After several washing steps the bands are developed by 0.05% 4-chloro-1-naphthol (Sigma, Munich, Germany) with 0.015% hydrogen peroxide in 20% methanol in TBS for 20 minutes.
- 15 Molecular weights are estimated for each band based on the distance migrated for ten known molecular weight standards (BenchMark, Invitrogen, Karlsruhe, Germany).

- 20 Digital image analysis and evaluation of the densitometric data of the electrophoretic separations are performed by means of the BioDocAnalyze™ software package (Biometra, Goettingen, Germany). BioDocAnalyze™ creates densitometric data files for each Western blot, which show the gray-intensity values (8-bit gray values) versus the Rf values (relative mobility, x-axis). BioDocAnalyze™ evaluates the height, area, molecular weight, Rf value, etc. of all peaks in this densitometric data file and also includes a photographic quality half tone bitmap.
- 25 From each densitometric data file, two vectors containing 50 variables are built in the following way: The Rf axis is broken into 50 classes such that each variable of the vector represents 1/50 of the Rf region between 0 and 1. For the Rf value of each peak of each electrophoretic lane, the corresponding class of the 50 vector variables is determined. This

class of the data vector is increased by the percent AUC (area under the curve) of this peak, which is calculated by BioDocAnalyze™. Thus, each variable of the data vector represents the percent area of the peaks of the electrophoretic lane at the corresponding Rf region. The data vectors are compiled into a database for subsequent calculations, and each of 5 them is randomly divided in two sub-sets: The test (unknown data, not used in the calculation procedure) and the training set (known data, used in the calculation procedure).

### **Calculation procedures**

10 Multivariate analysis of discriminance: As described above, BioDocAnalyze™ generates densitometric data files for each Western blot strip. Each data file is assigned to solely one of both predefined groups: "healthy" or "glaucoma". Based on these data vectors created by BioDocAnalyze™, a multivariate analysis of discriminance is performed. The analysis of discriminance can test the null-hypothesis that data vectors of the groups arise from a 15 multivariate normally-distributed population.

Artificial Neural Network (ANN): The multiple layer feedforward network (MLFN) with the backpropagation training algorithm is used as provided in the Statistica 6.0 software package (StatSoft, Tulsa, USA). All data vectors are presented to the network for the 20 learning process. The network used has 50 input neurons, 1 hidden layer, and 2 output neurons.

All patients exhibit different, complex staining patterns of auto-antibodies against retinal antigens and optic nerve head antigens. The number of peaks of Western blots against 25 retinal antigens is increased in sera of POAG patients compared to all other groups. Including all peaks the analysis of discriminance reveals a statistically significant difference between the patterns of POAG compared to all other groups ( $P<0.05$ ). The patterns of NTG patients ( $P>0.35$ ) and OHT patients ( $P>0.11$ ) are statistically not different from those of controls when retinal antigens are used (Fig. 1). Conversely, in Western blots 30 against optic nerve head antigens, it is the NTG group that reveals the highest variance from controls.

Furthermore, the antibody repertoires shown in Fig. 1 and 2 are analyzed by classification procedures (multivariate statistics and artificial neural networks). 95 % of patients can be correctly detected by the algorithm. The algorithm uses those regions of molecular weight that are found to be the most important to distinguish between the groups determined by

5 the sensitivity analysis of artificial neural networks. The analysis includes regions of already known antibodies, regions of unknown antibodies not described before, and especially regions where the reactivities in glaucoma patients are significantly lower than in healthy subjects.

10 Using these patterns to classify glaucoma patients, a responder operating characteristic (ROC) analysis is calculated and a r-value of approximately 0.85 is found, which is indicative of a good diagnostic test (Fig. 3).

**References**

15 <sup>1</sup> Quigley HA, *Br J Ophthalmol.* 1996; 80:385-387

<sup>2</sup> Quigley HA, *N Engl J Med.* 1993; 328(15):1097-1106

<sup>3</sup> Sommer A, *Arch Ophthalmol.* 1991; 109(8):1090-1095

<sup>4</sup> Wax MB, *Curr Opin Ophthalmol.* 2000; 11(2):145-150

<sup>5</sup> Tezel G, *Arch Ophthalmol.* 2000; 118(4):511-518

20 <sup>6</sup> Wax MB, *Arch Ophthalmol.* 1998; 116(8):993-1001

<sup>7</sup> Tezel G, *Invest Ophthalmol Vis Sci.* 1998; 39(12):2277-2287

<sup>8</sup> Tezel G, *J Neurosci.* 2000; 20(10):3552-3562

<sup>9</sup> Wax MB, *Ophthalmol.* 2001; 108(2):296-302

<sup>10</sup> Wax MB. A Model of Experimental Autoimmune Glaucoma in Rats Elicited by

25 Immunization With Heat Shock Protein 27. *ARVO Abstract*, 2002

<sup>11</sup> Salvador-Silva M, *J Neurosci Re.* 2001; 66(1):59-73

<sup>12</sup> Wax MB, *Am J Ophthalmol.* 1998; 125(2):145-157

<sup>13</sup> Romano C, *Invest Ophthalmol Vis Sci.* 1995; 36(10):1968-1975

<sup>14</sup> Tezel G, *Arch Ophthalmol.* 1999; 117(7):917-9248

30 <sup>15</sup> Maruyama I, *Invest Ophthalmol Vis Sci.* 2000; 41(7):1657-1665

<sup>16</sup> Yang J, *Am J Ophthalmol.* 2001; 131(4):421-426

<sup>17</sup> Yan J, *Invest Ophthalmol Vis Sci.* 2001; 42(6):1273-1276

<sup>18</sup> Tezel G, *Invest Ophthalmol Vis Sci.* 2001; 42(8):1787-1794

<sup>19</sup> Tezel G, *J Neurosci*. 2000; 20(23):8693-700

<sup>20</sup> Yuan L, *Glia*. 2000; 32(1):42-50

<sup>21</sup> Kremmer S, *Clin Exp Immunol*. 2001; 125(2):211-5

<sup>22</sup> Ricard CS, *Exp Eye Res*. 2001; 73(4):433-447

5 <sup>23</sup> Clark AF, *FASEB J*. 2001; 15(7):1251-1253

<sup>24</sup> Rezaie T, *Science*. 2002; 295(5557):1077-1079

<sup>25</sup> Surgucheva I, *J Neurosci Res*. 2002; 68(1):97-106

<sup>26</sup> Suguchov A, *Cell Motil Cytoskeleton*. 2001; 49(4):218-228

<sup>27</sup> Avrameas S, *Immunol Today* 1991; 12:154-159

10 <sup>28</sup> Zimmermann CW, Eblen F, Herzau V, Reinauer KM, *Graefe's Archive for Clin. and Exp. Ophthalmology* 1989; 227:521-525

<sup>29</sup> Zimmermann CW, Grus FH, Dux R, *Electrophoresis* 1995; 16:941-947

<sup>30</sup> Grus FH, Augustin AJ, Toth-Sagi K, Koch F, *Adv Ther*. 1997; 14(1):8-13

<sup>31</sup> Grus FH, Augustin AJ, Koch F, Zimmermann CW, Lutz J, *Adv Ther*. 1996; 13(4):203.

15

8. Okt. 2002

Claims

1. A method for the diagnosis of glaucoma, characterized in that in a first step, auto-antibodies against ocular antigens are detected and measured in body fluids of an individual, and, in a second step, the auto-antibody pattern is correlated with corresponding patterns of healthy individuals and glaucoma patients.  
5
2. A method according to claim 1 wherein the ocular antigens are retinal antigens, optic nerve antigens, optic nerve head antigens, trabecular meshwork antigens, uveal antigens, or a mixture of such antigens.  
10
3. A method according to claim 1 wherein the body fluid is serum, tears, saliva, urine, aqueous humour, or vitreous body of the eye.
- 15 4. A method according to claim 1 wherein the auto-antibodies are detected and measured in a Western blot assay, chemiluminescence assay, ELISA, or RIA.
5. A method according to claim 1 wherein the auto-antibodies are detected and measured on a protein chip array using surface-enhanced laser desorption / ionization (SELDI) or  
20 matrix assisted laser desorption / ionization (MALDI) mass spectrometry techniques.
6. A method according to claim 1 wherein the technique to generate the auto-antibody pattern is based on digital image detection, processing, and analysis.
- 25 7. A method according to claim 1 wherein auto-antibodies are detected and measured in an individual's serum.
8. A method according to claim 1 wherein the change in the antibody pattern over time is used to assess the progression and/or severeness of glaucoma.
- 30 9. A method for assessing an individual's risk for developing glaucoma with or without an elevated intraocular pressure, characterized in that in a first step, auto-antibodies against ocular antigens are detected and measured in body fluids of the individual, and,

in a second step, the auto-antibody pattern is correlated with corresponding patterns of healthy individuals and glaucoma patients.

10. A kit for the diagnosis of glaucoma according to claim 1, comprising a ready-to-use  
5 ocular antigen mixture and chemicals and materials needed to perform the biochemical analysis.

**Abstract**

18. Okt. 2002

The invention relates to a method for the diagnosis of glaucoma based on the composition of auto-antibodies against ocular antigens in body fluids of individuals. The method is  
5 characterized in that in a first step, auto-antibodies against retinal and/or optic nerve head antigens are detected and measured in body fluids of an individual, and, in a second step, the auto-antibody pattern is correlated with corresponding patterns of healthy individuals and glaucoma patients. The invention further relates to a method for assessing an individual's risk for developing glaucoma, and to kits for use in the method of the  
10 invention.

18. Okt. 2002

- 18 -






Figure 1



**Figure 2**



**Figure 3**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

**BLACK BORDERS**

**IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

**FADED TEXT OR DRAWING**

**BLURRED OR ILLEGIBLE TEXT OR DRAWING**

**SKEWED/SLANTED IMAGES**

**COLOR OR BLACK AND WHITE PHOTOGRAPHS**

**GRAY SCALE DOCUMENTS**

**LINES OR MARKS ON ORIGINAL DOCUMENT**

**REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

**OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**